Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Probiotic shows promise for Parkinson's in small study

NCT ID NCT06487975

Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a daily probiotic supplement called Bacillus subtilis can change certain gut bacteria and blood markers in people with Parkinson's disease. Twenty-six participants took either the probiotic or a placebo for a period. The goal was to see if the supplement is acceptable and affects biomarkers linked to Parkinson's, not to treat symptoms directly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bacillus subtilis (a probiotic supplement)
What this could lead to
If the probiotic shows clear effects on gut or blood markers, it could point toward a new way to manage Parkinson's disease.
What could go wrong
This is a very small, early-stage study focused on biomarkers, not symptoms. The results may not lead to any treatment change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

May 2023

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Parkinson's disease * Able to provide written informed consent * Over 50 years old * Motor symptom duration over 12 months * Stable dopaminergic medication regime for at least 3 months Exclusion Criteria: * Use of probiotic supplements and probiotic-fortified foods (such as probiotic drinks and yoghurts) within past 3 months * Use of antibiotics within past 3 months * Previous gastrointestinal surgery or chronic organic bowel disorder * History of clinically significant motor fluctuations * History of postural instability or falls * Current smoker * Known or suspected allergy to probiotics * Regular use of antacids, proton pump inhibitors, laxatives or anti-diarrheal drugs * Use of hypoglycaemic or diabetes drugs * Participation in clinical trial of investigational medicinal product within past 3 months * Co-morbidities or other factors that, in the opinion of the investigator, make the patient unlikely to comply with study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • NHS Lothian

    Edinburgh, United Kingdom

  • Norwegian Centre for Movement Disorders, Stavanger University Hospital

    Stavanger, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.